Monte Rosa Therapeutics, Inc. GLUE 深 沪
等待开盘 11-10 09:30:00 美东时间
10.58
+0.010
+0.09%
华盛通- 最 高10.885
- 今 开10.83
- 成交量 136.72万股
- 最 低 10.28
- 昨 收 10.57
- 总市值 9.04亿
- 52周最高 25.77
- 市盈率 静 --
- 换手率 1.60%
- 52周最低 9.68
- 委 比 -77.99%
- 总股本 8545.01万
- 历史最高 45.56
- 量 比 0.87
- 振 幅 5.72%
- 历史最低 2.44
- 每 手 1
- 风险率 3.88%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 巴克莱维百济神州"超配"评级！目标价从415美元上调至446美元
今日重点评级关注：瑞银：维持Liberty Media"中性"评级，目标价从110美元升至1116美元；杰富瑞：维持伊诺维奥制药"买入"评级，目标价从3美元升至8美元
11-09 14:00
Wells Fargo Maintains Overweight on Monte Rosa Therapeutics, Lowers Price Target to $25
Wells Fargo analyst Derek Archila maintains Monte Rosa Therapeutics (NASDAQ:GLUE) with a Overweight and lowers the price target from $27 to $25.
11-06 22:34
Monte Rosa Therapeutics Q3 EPS $0.03 Beats $(0.29) Estimate, Sales $54.366M Beat $29.750M Estimate
Monte Rosa Therapeutics (NASDAQ:GLUE) reported quarterly earnings of $0.03 per share which beat the analyst consensus estimate of $(0.29) by 110.34 percent. This is a 109.09 percent increase over losses of $(0.33) per share from the same period last year. The company reported quarterly sales of $54....
11-05 20:34
Monte Rosa To Receive $37.5M Milestone Payment From Novartis Following Initiation Of Second Phase 2 Trial Of MRT-6160 In Psoriatic Arthritis
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that its collaborator Novartis has initiated a second Phase 2 clinical study for the VAV1-directed MGD MRT-6160 (DDY391) in people livin...
10-28 19:08
Monte Rosa Says Its Collaborator Novartis Initiates Second Phase 2 Clinical Study For VAV1-Directed MGD MRT-6160 In People Living With Active Moderate To Severe Psoriatic Arthritis
Phase 2 study to be conducted in participants with active moderate to severe psoriatic arthritis Novartis conducting study under global exclusive development and commercialization license agreement with Monte Rosa Monte Rosa to receive milestone payment based on first patient visit of Phase 2 clinic...
10-28 19:06
美股大行评级 | 瑞银维持康宁“买入”评级，上调目标价至201美元；大摩维持泛林集团“超配”评级
今日重点评级关注：Needham：维持iRhythm Holdings"买入"评级，目标价从192美元升至194美元；HC Wainwright & Co.：维持5E Advanced Materials"买入"评级，目标价从3.5美元升至6.75美元
10-06 16:45
美股大行评级 | 潜在涨幅1654.39%！Ascendiant Capital上调NRX Pharmaceuticals(NRXP)目标价至50美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持NRX Pharmaceuticals"买入"评级，目标价从49美元升至50美元；Ascendiant Capital：维持Atossa Therapeutics"买入"评级，目标价从24美元升至25美元
10-02 08:33
Monte Rosa Therapeutics Investigational Drug Shows Potential for Cardiovascular Disease
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) reported Phase 1 trial results for its inflammatory disease drug candidate MRT-8102, while outlining plans to advance the treatment into multiple Phase 2 studies. The biotechnology firm announced that its NEK7-directed molecular glue degrader demonstrated ...
10-02 00:44
GLUE Stock Soars Over 20% Pre-Market: What's Driving the Surge?
Monte Rosa Therapeutics Inc. (NASDAQ:GLUE) shares surged 20.03% to $14.32 in the pre-market session on Thursday as investors looked ahead to expanded Phase 1 data from the biotech’s experimental cardiovascular drug MRT-8102. The Boston-based clinical-stage biotechnology company said Wednesday that m...
10-01 18:34
Why Vicor Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket
Shares of Vicor Corp (NASDAQ:VICR) rose sharply in pre-market trading after the company raised its third-quarter sequential revenue growth guidance. Vicor raised its third-quarter sequential revenue growth guidance to above 30% from above 20% on higher vertical power delivery royalties. Vicor shares...
10-01 16:31
